Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alector, Inc.    ALEC

ALECTOR, INC.

(ALEC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
12.35(c) 12.63(c) 13.07(c) 13.23(c) 13.29(c) Last
463 460 382 338 745 476 805 113 376 364 Volume
+2.15% +2.27% +3.48% +1.22% +0.45% Change
More quotes
Financials (USD)
Sales 2020 24,1 M - -
Net income 2020 -190 M - -
Net cash position 2020 267 M - -
P/E ratio 2020 -5,49x
Yield 2020 -
Sales 2021 34,3 M - -
Net income 2021 -217 M - -
Net cash position 2021 275 M - -
P/E ratio 2021 -5,26x
Yield 2021 -
Capitalization 1 053 M 1 053 M -
EV / Sales 2020 32,6x
EV / Sales 2021 22,7x
Nbr of Employees 162
Free-Float 82,7%
More Financials
Company
Alector, Inc. is a clinical-stage biopharmaceutical company focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to... 
More about the company
Notations Surperformance© of Alector, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ALECTOR, INC.
11/18ALECTOR : Corporate Presentation November 2020
PU
11/11ALECTOR : to Present at the Stifel 2020 Virtual Healthcare Conference
AQ
11/11Alector to Present at the Stifel 2020 Virtual Healthcare Conference
GL
11/10ALECTOR : 3Q Earnings Snapshot
AQ
11/10ALECTOR : Management's Discussion and Analysis of Financial Condition and Result..
AQ
11/10ALECTOR, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
11/10ALECTOR : Reports Third Quarter 2020 Financial Results and Provides Corporate Up..
AQ
11/10Alector Reports Third Quarter 2020 Financial Results and Provides Corporate U..
GL
11/03PREVAIL THERAPEUTICS : Announces Decisive Victory in Arbitration Brought by Alec..
AQ
11/02ALECTOR : Provides Update on Arbitration Proceedings with Dr. Asa Abeliovich
AQ
11/02Alector Provides Update on Arbitration Proceedings with Dr. Asa Abeliovich
GL
10/23ALECTOR : to Highlight Early-Stage Cancer Programs at Upcoming Scientific Forums
AQ
10/22ALECTOR : to Highlight Early-Stage Cancer Programs at Upcoming Scientific Forums
AQ
10/22Alector to Highlight Early-Stage Cancer Programs at Upcoming Scientific Forum..
GL
10/06ALECTOR, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,..
AQ
More news
News in other languages on ALECTOR, INC.

- No features available -

More news
Chart ALECTOR, INC.
Duration : Period :
Alector, Inc. Technical Analysis Chart | ALEC | US0144421072 | MarketScreener
Technical analysis trends ALECTOR, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 33,63 $
Last Close Price 13,29 $
Spread / Highest target 231%
Spread / Average Target 153%
Spread / Lowest Target 111%
EPS Revisions
Managers
NameTitle
Arnon Rosenthal Chief Executive Officer & Director
Shehnaaz Suliman President & Chief Operating Officer
Tillman U. Gerngross Chairman
Calvin Yu Vice President-Finance
Robert Paul Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALECTOR, INC.-22.87%1 053
GILEAD SCIENCES, INC.-8.43%75 525
VERTEX PHARMACEUTICALS-0.39%56 298
REGENERON PHARMACEUTICALS35.38%53 416
WUXI APPTEC CO., LTD.55.32%38 761
BIONTECH SE209.80%24 529